RALIVIA 100 MG
TRAMADOL HYDROCHLORIDE : 100 MG · DIN 02299194 · BAUSCH HEALTH, CANADA INC.
Health Canada status: MARKETED
What is RALIVIA?
RALIVIA 100 MG contains TRAMADOL HYDROCHLORIDE : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02299194, held by BAUSCH HEALTH, CANADA INC., supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 25-Jun-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is RALIVIA used for?
Management of moderate to moderately severe pain in adults who require continuous treatment for several days or more.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02299194 |
|---|---|
| Brand name | RALIVIA |
| Generic / active ingredient | TRAMADOL HYDROCHLORIDE : 100 MG |
| Manufacturer | BAUSCH HEALTH, CANADA INC. |
| Strength | 100 MG |
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | N02AX02 TRAMADOL |
| AHFS class | 28:08.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 25-Jun-2021 |
| Original market date | 2007-10-25 00:00:00 |
How is it administered?
Once daily (24-hour intervals). Swallow whole. Initial: 100 mg/day. Titrate by 100 mg every 5 days. Max: 300 mg/day. Taper gradually when discontinuing.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (standard section 11 reference), but usually 15-30°C. Secure storage required to avoid theft/misuse.
How is it supplied?
Bottles of 90 tablets.
Contraindications
Hypersensitivity to tramadol/opioids; GI obstruction; suspected surgical abdomen; severe renal/hepatic impairment; asthma/respiratory depression; acute alcoholism; MAOIs (within 14 days); <12 years.
Warnings and precautions
Risks of addiction, abuse, misuse; life-threatening respiratory depression; fatal if crushed/chewed; accidental ingestion can be fatal; risk of seizures and serotonin syndrome.
What can be used instead?
Other Canadian products sharing ATC code N02AX02 TRAMADOL. 22 of 25 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-TRAMADOL | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 02426153 |
| AURO-TRAMADOL | 50 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02479672 |
| DURELA | 100 MG | CAPSULE (EXTENDED RELEASE) | CIPHER PHARMACEUTICALS INC | MARKETED | DIN 02373017 |
| DURELA | 200 MG | CAPSULE (EXTENDED RELEASE) | CIPHER PHARMACEUTICALS INC | MARKETED | DIN 02373025 |
| DURELA | 300 MG | CAPSULE (EXTENDED RELEASE) | CIPHER PHARMACEUTICALS INC | MARKETED | DIN 02373033 |
| JAMP TRAMADOL HCL | 50 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02518759 |
| MAR-TRAMADOL | 50 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02480859 |
| RALIVIA | 200 MG | TABLET (EXTENDED-RELEASE) | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02299208 |
| RALIVIA | 300 MG | TABLET (EXTENDED-RELEASE) | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02299216 |
| TARO-TRAMADOL ER | 100 MG | TABLET (EXTENDED-RELEASE) | TARO PHARMACEUTICALS INC | MARKETED | DIN 02450429 |
Who else supplies TRAMADOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TRAMADOL appears in 695 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.